Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Projected timelines from industry analysts suggest: Phase 3 trials may begin in late 2024 or 2025
When to contact your healthcare professional : Seek medical advice if you experience significantly elevated blood glucose readings (consistently above 15 mmol/L) or symptoms of hyperglycaemia (excessive thirst, frequent urination, fatigue) Seek urgent medical attention for severe, persistent abdominal pain (with or without vomiting) which could indicate pancreatitis, or symptoms of gallbladder disease (right upper abdominal pain, fever, jaundice) Contact your GP if you are considering stopping your medication Never discontinue prescribed diabetes treatment without medical supervision
The clinical trials showed it can lower HbA1c levels and help with weight loss
Single-Agent GLP-1 Therapy Remains the Clinical Standard Evidence from the SUSTAIN and SURMOUNT clinical trials demonstrates that monotherapy with either tirzepatide or semaglutide produces sustained weight reductions of 1522% when properly dosed over 68 weeks
Red Rock tirzepatide with glycine formulations fall into this differentiated category
Patients should discuss these medications' possible risks and benefits with their healthcare provider to determine the most appropriate treatment option
